Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Solid Tumor 1Ovarian Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Breast Neoplasm Female 1Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed 1

Interventions

pertuzumab 1penpulimab 1dalpiciclib 1Trastuzumab 1Patient Reported Outcome Measures 1Induction Chemotherapy 1Fulvestrant 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasm Female × dalpiciclib × Clear all
NCT05577442 2022-10-19

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Phase 2 Unknown
52 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡